Incyte Corporation
115.71USD
-1.2200 (-1.04%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on INCY.
Valuation
P/E (TTM)
16.38x
P/E (Forward)
13.39x
EV/EBITDA
11.11x
EV/Revenue
3.54x
P/S (TTM)
4.37x
P/B
4.17x
FCF Yield
3.80%
Dividend Yield
0.00%
Gross Margin
92.47%
Operating Margin
30.05%
Net Margin
26.71%
Peer Comparison — Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| INCYIncyte Corporation | $23.45B | 16.38x | 11.11x | 3.80% | 20.87% | 0.00% |
| VRTXVertex Pharmaceuticals Incorporated | $132.71B | 30.51x | 24.88x | 1.98% | 12.50% | 0.00% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $82.88B |
| 19.91x |
| 15.97x |
| 3.70% |
| 16.70% |
| 0.47% |
| MRNAModerna, Inc. | $79.89B | — | — | 0.37% | 2.10% | 0.00% |
| ARGXargenx SE | $54.94B | 30.26x | 715.84x | — | 52.10% | 0.00% |
| RPRXRoyalty Pharma plc | $36.90B | 33.97x | 25.37x | -3.24% | 16.50% | 1.47% |
| ROIVRoivant Sciences Ltd. | $26.36B | — | — | -4.24% | -33.50% | 0.00% |
| BNTXBioNTech SE | $22.13B | — | — | -1.13% | -59.50% | 0.00% |
| ASNDAscendis Pharma A/S | $16.01B | 18.65x | 59.29x | 0.08% | 114.70% | 0.00% |